Ultrasound pain management device makes way for new FDA category
The US Food and Drug Administration created a new category for ZetrOZ's Acoustic Medicine device.
ZetrOZ, a medical technology company that produces wearable ultrasound devices to reduce pain and inflammation, now comes under a new FDA category, created for just these types of therapeuties.
ZetrOZ's sustained acoustic medicine device is an at-home, long-duration ultrasound therapy instrument, where patients, such as teenage and adult athletes recovering from sports injuries get trained on the use of the device, and then can apply it directly at home. The device can treat inflammation, pain, and other unresolved medical issues such as cartilage degeneration, miniscus injuries and ankle sprains. The localized treatment allows healing without a surgical procedure, and is typically applied once a day for 6 to 8 weeks.
The FDA initially cleared ZetrOZ's sustained acoustic medicine device in 2013, with expanded indications in 2020.
This article was originally posted on Contemporary Pediatrics®.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
